Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics, Inc. (PSTV) will release its fourth quarter and full year 2021 financial results on February 24, 2022, after market close. Following the announcement, a conference call will be held at 5:00 p.m. ET to discuss the results and provide a corporate update. The call will be accessible via a live webcast on the company's investor relations page. Plus Therapeutics develops innovative radiotherapeutics for hard-to-treat cancers and is evaluating its lead product, Rhenium-186 NanoLiposome, in clinical trials.
Plus Therapeutics (Nasdaq: PSTV) announced that Marc H. Hedrick M.D., President and CEO, will present at the BIO CEO & Investor Conference on February 14, 2022, at 1:15 p.m. ET in New York City. The presentation will provide an overview of the company's innovative radiotherapeutics for rare cancers, focusing on their lead product, Rhenium-186 NanoLiposome, currently evaluated in clinical trials for treating recurrent glioblastoma. The live presentation can be accessed by registered participants via the conference website.
AUSTIN, Texas, Jan. 07, 2022 - Plus Therapeutics (Nasdaq: PSTV) announced that Marc H. Hedrick, M.D., will speak at two virtual conferences this January. The H.C. Wainwright BioConnect Conference will take place from January 10-13, with presentations available on demand starting January 10 at 7:00 a.m. ET. Additionally, the Biotech Showcase 2022 is scheduled for January 10-12 and 17-19, with on-demand access for presentations. Webcast replays and further information can be found on their website.
Plus Therapeutics has secured a worldwide exclusive license from UT Health San Antonio to develop innovative interventional radiotherapeutics for solid organ cancers. This deal enhances their proprietary Rhenium NanoLiposome technology, aiming to deliver targeted cancer therapies, specifically for liver cancer. The licensed technology includes biodegradable alginate microspheres to block blood flow to tumors while delivering high doses of cytotoxic compounds. An IND submission for liver cancer treatment is planned for 2022, tapping into a $1.3 billion market opportunity.
Plus Therapeutics (PSTV) has achieved key milestones in developing Rhenium-186 NanoLiposome (186RNL) radiotherapeutic. The company signed a master services agreement with IsoTherapeutics Group for cGMP grade Rhenium-186 isotope manufacturing, ensuring compliance with FDA standards for clinical trials. This agreement is expected to facilitate future clinical and commercial supply contracts. Furthermore, Plus Therapeutics has transferred analytical test methods to Piramal Pharma Solutions, paving the way for the cGMP drug product intermediate manufacturing, crucial for ongoing trials targeting difficult-to-treat cancers.
Plus Therapeutics (Nasdaq: PSTV) announced that Marc H. Hedrick, M.D., President & CEO, will present at the MedInvest Oncology Investor Conference on December 7, 2021, at 12:00 p.m. ET. The presentation will cover the company's innovative radiotherapeutics for rare cancers. A pre-recorded webcast of the presentation and a live Q&A will be available on the company's Investor Relations page. Plus Therapeutics focuses on developing advanced cancer treatments using novel liposomal encapsulation technology aimed at enhancing drug delivery and patient outcomes.
Plus Therapeutics (PSTV) has reported positive interim results from its Phase 1 ReSPECT™-GBM clinical trial, focusing on the investigational drug Rhenium-186 NanoLiposome (186RNL) for recurrent glioblastoma (GBM). The study revealed it is well-tolerated with no dose-limiting toxicities. Patients receiving more than 100 Gy of radiation experienced a mean overall survival of 453.8 days. The trial has evaluated 22 patients over six years, and significant delivery parameters were noted, supporting further clinical investigations.
Plus Therapeutics, Inc. (PSTV) announced the granting of option awards to Dr. Norman LaFrance on November 11, 2021, as part of his induction as Chief Medical Officer. The awards include options to purchase up to 120,000 shares of common stock, vesting over four years with specific conditions related to Dr. LaFrance's continued service. This move aims to align his interests with those of the shareholders. The options were granted outside of the company's 2020 Incentive Plan but follow similar terms. Plus Therapeutics is focused on innovative treatments for cancer.
Plus Therapeutics (NASDAQ: PSTV) has received Fast Track designation from the FDA for its Rhenium-186 NanoLiposome (186RNL) aimed at treating leptomeningeal metastases (LM). This condition affects 5% of cancer patients, often resulting in severe health complications. The company expects to begin patient accrual for the ReSPECT-LM Phase 1 clinical trial in Q4 2021. The Fast Track status allows for accelerated communication with the FDA, potentially speeding up the development and approval process.
Plus Therapeutics (PSTV) announced a webinar on November 18, 2021, from 4:00 to 5:00 p.m. ET, discussing the ReSPECT-GBM trial data. Key opinion leaders will present findings on the safety and efficacy of Rhenium-186 NanoLiposome in treating recurrent glioblastoma. Speakers include Dr. Andrew J. Brenner, who will provide trial updates, and Dr. Toral Patel, who will discuss convection enhanced delivery in neurosurgery. The webinar allows for analyst and public Q&A. Data will also be presented at the Society for Neuro-Oncology Annual Meeting on November 19, 2021.